SAT0326 Duration of remission and minimal disease activityafter starting and discontinuation of biologic (B) dmards in early psoriatic arthritis patients treated according to treat-to-target strategy (results of an open-label remarca study)

E Loginova,T Korotaeva,S Glukhova,E Nasonov,E Gubar

doi:10.1136/annrheumdis-2018-eular.3245

SAT0326 Duration of remission and minimal disease activityafter starting and discontinuation of biologic (B) dmards in early psoriatic arthritis patients treated according to treat-to-target strategy (results of an open-label remarca study)

E Loginova, T Korotaeva + Show 3 more

Open Access

https://doi.org/10.1136/annrheumdis-2018-eular.3245

Copy DOI

Journal: Annals of the Rheumatic Diseases

Publication Date: Jun 1, 2018

Affiliation: VA Nasonova Scientific Research Institute of Rheumatology

#Disease Activity Index For Psoriatic Arthritis #Minimal Disease Activity + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

BackgroundThe main goal of treat-to-target (T2T) strategy in psoriatic arthritis (PsA) is achievement of remission (REM) or minimal disease activity (MDA). There is limited data concerning the duration of REM/MDA...

Full Text

Paper version not known

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Annals of the Rheumatic Diseases

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.